Apimeds Pharmaceuticals US, Inc 8-K, filed Oct 13, 2026
Apimeds Pharmaceuticals US, Inc. (APUS)
About this 8-K
Apimeds Pharmaceuticals US, Inc filed this 8-K on October 13, 2026, reporting on events of October 4, 2026.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
| (Address of principal executive offices) | (Zip code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
BlockAssure Agreement
On October 4, 2026, MindWave Innovations Inc. (“MindWave”), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (the “Company”), issued a press release announcing that it had entered into a two-year Master Service Agreement with BlockAssure Inc., a Delaware corporation (“BlockAssure”), under which MindWave will build, deploy, operate and maintain AssureChain, a dedicated subnet of MindChain for recording and executing BlockAssure’s insurance contracts, reinsurance treaties, insurance policies and claims processes on-chain. The agreement renews automatically for successive one-year periods unless either party gives notice of non-renewal. Consideration consists of a fixed development fee payable in quarterly installments, operate and maintenance fees to be agreed, and an allocation to MindWave of AssureCoin, a digital token BlockAssure plans to create on MindChain, equal to 20% of its total supply. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.
Forward-Looking Statements
All statements, other than statements of historical fact, included in this report that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. Words such as “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “potential,” “create,” “intend,” “could,” “would,” “may,” “plan,” “will,” “guidance,” “look,” “goal,” “future,” “build,” “focus,” “continue,” “strive,” “allow” or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking.
There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this report, including risks relating to development timelines, milestone achievement, acceptance testing, technical performance, integration with third-party systems and data sources, BlockAssure’s ability to obtain and maintain required insurance, reinsurance and other licenses, whether and when AssureCoin is created and the value of any token consideration, the parties’ ability to agree on operate and maintenance fees, market acceptance, and regulatory requirements applicable to insurance, reinsurance and digital assets. All forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this current report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release issued by MindWave Innovations Inc. dated October 4, 2026 (BlockAssure). | |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Apimeds Pharmaceuticals US, Inc. | ||
| Date: October 13, 2026 | By: | /s/ Dr. Vin Menon |
| Name: | Dr. Vin Menon | |
| Title: | Co-Chief Executive Officer | |
| By: | /s/ SungJoon Chae | |
| Name: | SungJoon Chae | |
| Title: | Co-Chief Executive Officer | |
2
Exhibit 99.1
MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network
AssureChain, a dedicated subnet of MindChain, will run every insurance function on-chain, while MindChain provides settlement and anchoring to Ethereum
MATAWAN, New Jersey, Oct. 4, 2026 – via IBN – MindWave Innovations Inc. USA (“MindWave”), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has signed a 2-year master maintenance and service agreement with Delaware-based BlockAssure Inc. (“BlockAssure”) to build, deploy and operate AssureChain, a dedicated subnet of MindChain that will run BlockAssure’s insurance and reinsurance operations on-chain.
For MindWave, this is an important expansion of its U.S. business. It takes the company’s technology work into insurance and reinsurance, and it is a long-term build-and-operate contract with a U.S. client.
“BlockAssure chose us to build AssureChain, and it is exactly the kind of work we want to do for U.S. clients,” said Dr. Vin Menon, Chief Executive Officer of MindWave Innovations Inc. USA.
MindWave will design, develop, security-audit and deploy AssureChain, then host, operate and maintain it once it goes live. All of BlockAssure’s insurance work will happen on AssureChain: contracts, policies, premium and payment entries, reinsurance treaties and claims processing, from the start of a policy to the settlement of a claim. MindChain’s job is narrower – It provides the settlement layer and anchors AssureChain’s records to Ethereum.
MindWave will earn contracted development fees, payable in quarterly installments, with later operating and maintenance fees to be agreed. The agreement also provides for an allocation to MindWave equal to 20% of the total supply of AssureCoin, a digital token BlockAssure plans to create within the MindChain network, delivered when the token is created. The allocation is fully vested on delivery, and anti-dilution terms maintain MindWave’s 20% share if additional AssureCoin is issued during the term or for two years afterward.
The aim is straightforward: BlockAssure handles the market relationships, and MindWave builds and runs the network underneath them. Contracts, policies, payments, treaties and claims all run on AssureChain. Because it settles through MindChain and anchors to Ethereum, you can follow any claim from the policy that created it to the recovery that closes it outFor the length of the agreement, MindWave is BlockAssure’s exclusive blockchain provider for AssureChain.
The two companies have divided the work along clear lines. BlockAssure will lead underwriting and claims decisions, licensing, and its relationships with insurers, reinsurers and brokers. MindWave supplies the infrastructure and the technical services needed to run AssureChain. It acts only as the technology provider.
AssureChain is made up of four modules and a data oracle: insurance contracts; policy issuance and lifecycle management, including premium and payment entries; reinsurance treaties and facultative placements; and claims processing from notification through assessment, settlement and reinsurance recovery. The oracle feeds verified parametric, environmental, catastrophe, market and identity data onto AssureChain, which lets a parametric claim trigger automatically once a pre-agreed threshold is met.
Each claim on AssureChain can be traced back to the policy, contract and treaty it came from, and MindChain anchors those records to Ethereum. BlockAssure and its counterparties therefore work from one verifiable record, from placement to settlement. Each module will be independently security-audited before production, and personal data will not be written on-chain except in hashed or tokenized form.
The agreement took effect on Oct. 4, 2026. Development is planned over four quarters against agreed milestones, and BlockAssure will acceptance-test each module. Once the first module is accepted, MindWave takes on hosting, validator operations, maintenance, security patches and helpdesk support.
After the initial 2-year term, the agreement renews automatically for one-year periods unless either party gives 90 days’ notice.
About MindWave Innovations Inc. USA
MindWave Innovations Inc. USA, a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), develops technology infrastructure and digital solutions for blockchain-enabled applications, data-driven platforms, and emerging commercial ecosystems.
Through projects such as AssureChain, MindWave is expanding the application of its technology into insurance, reinsurance and digital-asset-enabled insurance models.
For more information, visit https://www.mindwaveinnovations.com/
About MindChain
MindChain is a blockchain infrastructure developed within the MindWave ecosystem to support transparent, traceable, and verifiable digital transactions. It is designed to provide the underlying ledger capabilities required for applications involving digital assets, registries, tokenized ecosystems, and decentralized services.
About AssureChain
AssureChain is BlockAssure’s dedicated insurance and reinsurance network and runs as a subnet of MindChain. Every insurance function runs on AssureChain. MindChain handles settlement and anchoring to Ethereum.
About BlockAssure Inc.
BlockAssure Inc. is a Delaware corporation developing an insurance and reinsurance platform supported by digital asset capital.
For more information, visit https://www.blockassure.io/
Forward-Looking Statements
This announcement contains forward-looking statements regarding the development, implementation, anticipated capabilities, and potential performance of AssureChain, and the potential creation and allocation of AssureCoin. These statements are based on current expectations and are subject to risks and uncertainties, including development timelines, achievement of project milestones, technical performance, regulatory requirements, BlockAssure’s licensing, whether and when AssureCoin is created, and market acceptance. Actual results may differ materially from those expressed or implied. The company undertakes no obligation to update these statements except as required by applicable law.
Media:
MindWave Innovations Inc.
contact@mindwaveinnovations.com
Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai